@article{9b180e083380428db7209e773b0ad388,
title = "Sulfonium-Stapled Peptides-Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention",
abstract = "Neoantigen peptides hold great potential as vaccine candidates for tumor immunotherapy. However, due to the limitation of antigen cellular uptake and cross-presentation, the progress with neoantigen peptide-based vaccines has obviously lagged in clinical trials. Here, a stapling peptide-based nano-vaccine is developed, comprising a self-assembly nanoparticle driven by the nucleic acid adjuvant-antigen conjugate. This nano-vaccine stimulates a strong tumor-specific T cell response by activating antigen presentation and toll-like receptor signaling pathways. By markedly improving the efficiency of antigen/adjuvant co-delivery to the draining lymph nodes, the nano-vaccine leads to 100\% tumor prevention for up to 11 months and without tumor recurrence, heralding the generation of long-term anti-tumor memory. Moreover, the injection of nano-vaccine with signal neoantigen eliminates the established MC-38 tumor (a cell line of murine carcinoma of the colon without exogenous OVA protein expression) in 40\% of the mice by inducing potent cytotoxic T lymphocyte infiltration in the tumor microenvironment without substantial systemic toxicity. These findings represent that stapling peptide-based nano-vaccine may serve as a facile, general, and safe strategy to stimulate a strong anti-tumor immune response for the neoantigen peptide-based personalized tumor immunotherapy.",
keywords = "nano-carriers, neoantigens, personalized immunotherapy, stapling peptide, sulfonium",
author = "Yaping Zhang and Leying Jiang and Siyong Huang and Chenshan Lian and Huiting Liang and Yun Xing and Jianbo Liu and Xiaojing Tian and Zhihong Liu and Rui Wang and Yuhao An and Fei Lu and Youdong Pan and Wei Han and Zigang Li and Feng Yin",
note = "Funding information: The authors acknowledge financial support from the National Basic Research Program of China 973 program (2021YFC2103900, to F.Y.; 2021YFA0910803, to Z.G.L.), the Natural Science Foundation of China grants (21977010, to F.Y.; 22307086, to Y.P.Z.; 21977011, to W.H.), National Center for Biological Medicine Technology Innovation (NCTIB2022HS01017, to Z.G.L.). The authors acknowledge financial support from the Natural Science Foundation of Guangdong Province (2022A1515010996, to F.Y.); Shenzhen Science and Technology Program (RCJC20200714114433053, to Z.G.L.; JCYJ20200109140406047, to F.L.; JCYJ20220818095808019, to C.W.; and JCYJ20210324102809026, to R.X.), High-tech Zone Development Special Project of Shenzhen (29853M-KCJ-2023-002-07 to Z.G.L.). Shenzhen Fundamental Research Program (GXWD20201231165807007-20200827170132001, to W.H.). The authors acknowledge financial support from Tian Fu Jin Cheng Laboratory (Advanced Medical Center) Group Racing Project (TFJC2023010008, to Z.G.L.). The authors acknowledge financial support from the Beijing National Laboratory of Molecular Science open grant (BNLMS20160112, to Z.G.L.) and Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions grant (2019SHIBS0004, to Z.G.L.). This work is supported by the Proteomic Platform of Pingshan Translational Medicine Center, Shenzhen Bay Laboratory. This work is also supported by the High-Performance Computing Platform of Peking University. The authors thank Prof. Xingjie Liang of the National Center for Nanoscience and Technology (Beijing, China) for providing the B16-OVA and DC2.4 cells. Publisher Copyright: {\textcopyright} 2024 The Authors. Advanced Science published by Wiley-VCH GmbH.",
year = "2024",
month = jun,
day = "26",
doi = "10.1002/advs.202307754",
language = "English",
volume = "11",
journal = "Advanced Science",
issn = "2198-3844",
publisher = "Wiley-VCH Verlag",
number = "24",
}
